162 related articles for article (PubMed ID: 17920164)
41. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies.
Voges B; Vallbracht S; Zimmer G; Bossow S; Neubert WJ; Richter K; Hobeika E; Herrler G; Ehl S
Cell Immunol; 2007 Jun; 247(2):85-94. PubMed ID: 17904538
[TBL] [Abstract][Full Text] [Related]
42. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
[TBL] [Abstract][Full Text] [Related]
43. Viral infection modulates expression of hypersensitivity pneumonitis.
Gudmundsson G; Monick MM; Hunninghake GW
J Immunol; 1999 Jun; 162(12):7397-401. PubMed ID: 10358192
[TBL] [Abstract][Full Text] [Related]
44. Lack of effect of bovine lactoferrin in respiratory syncytial virus replication and clinical disease severity in the mouse model.
Gualdi L; Mertz S; Gomez AM; Ramilo O; Wittke A; Mejias A
Antiviral Res; 2013 Aug; 99(2):188-95. PubMed ID: 23735300
[TBL] [Abstract][Full Text] [Related]
45. Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults.
You D; Becnel D; Wang K; Ripple M; Daly M; Cormier SA
Respir Res; 2006 Aug; 7(1):107. PubMed ID: 16893457
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of CD8+ T lymphocytes attenuates respiratory syncytial virus-enhanced allergic inflammation.
Jiang XB; Wang ZD; Zhu Y; Zhang XL; Cui XF; Yao K; Yin KS
Respiration; 2009; 77(1):76-84. PubMed ID: 18818487
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge.
de Waal L; Power UF; Yüksel S; van Amerongen G; Nguyen TN; Niesters HG; de Swart RL; Osterhaus AD
Vaccine; 2004 Feb; 22(8):915-22. PubMed ID: 15161068
[TBL] [Abstract][Full Text] [Related]
48. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines.
Moghaddam A; Olszewska W; Wang B; Tregoning JS; Helson R; Sattentau QJ; Openshaw PJ
Nat Med; 2006 Aug; 12(8):905-7. PubMed ID: 16862151
[TBL] [Abstract][Full Text] [Related]
49. [Primary respiratory syncytial virus infection in mice].
Zou Y; Huang H; Xu J
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Aug; 24(8):484-6. PubMed ID: 11718040
[TBL] [Abstract][Full Text] [Related]
50. Respiratory syncytial virus protects against the subsequent development of Japanese cedar pollen-induced allergic responses.
Liu B; Kimura Y
J Med Virol; 2007 Oct; 79(10):1600-5. PubMed ID: 17705182
[TBL] [Abstract][Full Text] [Related]
51. An assessment of different DNA delivery systems for protection against respiratory syncytial virus infection in the murine model: gene-gun delivery induces IgG in the lung.
Tree JA; Bembridge G; Hou S; Taylor G; Fashola-Stone E; Melero J; Cranage MP
Vaccine; 2004 Jun; 22(19):2438-43. PubMed ID: 15193407
[TBL] [Abstract][Full Text] [Related]
52. Co-immunization of BALB/c mice with recombinant immunogens containing G protein fragment and chimeric CTL epitope of respiratory syncytial virus induces enhanced cellular immunity and high level of antibody response.
Fan CF; Mei XG
Vaccine; 2005 Aug; 23(35):4453-61. PubMed ID: 15935522
[TBL] [Abstract][Full Text] [Related]
53. Immunity and immunopathology to respiratory syncytial virus. The mouse model.
Openshaw PJ
Am J Respir Crit Care Med; 1995 Oct; 152(4 Pt 2):S59-62. PubMed ID: 7551415
[TBL] [Abstract][Full Text] [Related]
54. Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells.
Nallet S; Amacker M; Westerfeld N; Baldi L; König I; Hacker DL; Zaborosch C; Zurbriggen R; Wurm FM
Vaccine; 2009 Oct; 27(46):6415-9. PubMed ID: 19559121
[TBL] [Abstract][Full Text] [Related]
55. The future of respiratory syncytial virus vaccine development.
Polack FP; Karron RA
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
[TBL] [Abstract][Full Text] [Related]
56. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.
Zhang W; Tripp RA
J Virol; 2008 Dec; 82(24):12221-31. PubMed ID: 18818323
[TBL] [Abstract][Full Text] [Related]
57. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
Langley JM; Sales V; McGeer A; Guasparini R; Predy G; Meekison W; Li M; Capellan J; Wang E
Vaccine; 2009 Sep; 27(42):5913-9. PubMed ID: 19651171
[TBL] [Abstract][Full Text] [Related]
58. Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine.
Remot A; Roux X; Dubuquoy C; Fix J; Bouet S; Moudjou M; Eléouët JF; Riffault S; Petit-Camurdan A
PLoS One; 2012; 7(5):e37722. PubMed ID: 22655066
[TBL] [Abstract][Full Text] [Related]
59. DSCG reduces RSV-induced illness in RSV-infected mice.
Hashimoto K; Mori S; Hashimoto Y; Kaneko H; Ishibashi K; Ishioka K; Kawasaki Y; Peebles RS; Munakata M; Hosoya M; Suzutani T
J Med Virol; 2009 Feb; 81(2):354-61. PubMed ID: 19107959
[TBL] [Abstract][Full Text] [Related]
60. Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus.
Ternette N; Tippler B; Uberla K; Grunwald T
Vaccine; 2007 Oct; 25(41):7271-9. PubMed ID: 17825960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
